Concerns Over Power Morcellators Mount, as Bernstein Liebhard LLP Notes New Finding that Uterine Morcellation May Spread Benign Disease

Share Article

The publication of this latest power morcellator study follows warnings from U.S. health regulators regarding the potential for uterine morcellation to spread undetected uterine sarcomas and other gynecological cancers.

Free Case Review
The publication of this study follows two warnings from U.S. health regulators regarding the potential for morcellation to spread uterine sarcomas and other undiagnosed gynecological cancers.

A newly published study has found that the use of power morcellators ( ) to remove uterine fibroids may result in the dissemination of benign disease, adding to growing concerns about the safety of such procedures, Bernstein Liebhard LLP reports. The research, which is published in the January issue of Obstetrics and Gynecology, looked at the cases of three women who underwent uterine morcellation to remove fibroids. According to an abstract posted on the journal’s website, each patient later had to undergo a laparotomy and extensive, multi-organ resection after the benign disease spread into their peritoneal cavity. The authors of the report concluded that power morcellation of the uterus may be associated with clinically significant dissemination of benign uterine disease.*

“The publication of this study follows two warnings from U.S. health regulators regarding the potential for morcellation to spread uterine sarcomas and other undiagnosed gynecological cancers. This study just confirms that these procedures can be associated with very significant risks and complications,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is providing free legal consultations to women who were diagnosed with advanced uterine cancers following uterine morcellation.

Uterine Morcellation and Cancer
Power morcellators are used in minimally-invasive uterine surgeries to cut up tissue into small pieces so that it can be removed from the body via a small abdominal incision. In April, the U.S. Food & Drug Administration (FDA) discouraged doctors from using the devices in minimally invasive hysterectomies and fibroid removals because of concerns that they could promote the spread of undetected uterine cancers. **

On November 24th, the FDA issued a second alert, and announced that it would ask power morcellator manufacturers to add a new black box warning to their labels regarding their potential to disseminate cancer cells. The alert noted that the prevalence of unsuspected uterine sarcoma in patients undergoing such procedures is 1 in 352, while the prevalence of unsuspected uterine leiomyosarcoma is 1 in 498, which is higher than previously thought. The FDA is now advising against uterine morcellation for the majority of women who require hysterectomies or fibroid removal surgery.

Women who allegedly experienced the spread of uterine sarcoma or other cancers due to a power morcellator may be able to take legal action against the manufacturer of the device. To learn more about the risks potentially associated with uterine morcellation, please visit Bernstein Liebhard LLP's website. To obtain a free legal review, please call 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

*, Obstetrics and Gynecology, January 2015
**, FDA, April 17, 2014

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website